Late response to radiochemotherapy in pediatric glioblastoma: Report on two patients treated according to HIT-GBM protocols

被引:3
作者
Classen, C. F.
Warmuth-Metz, M.
Papke, K.
Trotter, A.
Wolff, J. E. A.
Wagner, S.
机构
[1] Childrens Hosp, Wedau Klin, Klinikum Duisburg, D-47055 Duisburg, Germany
[2] Univ Childrens Hosp, Rostock, Germany
[3] Univ Wurzburg, Dept Neuroradiol, Wurzburg, Germany
[4] Klinikum Duisburg, Wedau Klin, Clin Radiol & Neuroradiol, Duisburg, Germany
[5] Hegau Klinikum GmbH, Singen, Germany
[6] Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Pediat Neurooncol Sect, Houston, TX 77030 USA
[7] Univ Regensburg, Dept Pediat Oncol, D-8400 Regensburg, Germany
关键词
glioblastoma; response control; radiochemotherapy; pediatric;
D O I
10.1080/08880010600951088
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade gliomas in children are rare and the best treatment is undetermined. The German language group study HIT-GBM compares various induction protocols for subsequent patient cohorts. Currently, cisplatinum, etoposide, ifosfamide, and vincristine are given simultaneously with extended-field radiotherapy. Imaging is done 3 weeks after to define treatment response, followed by 6-weekly controls during consolidation with lomustine, vincristine, and prednisone. The authors report on 2 patients with incompletely resected glioblastoma multiforme in which response was lacking 3 weeks after radiochemotherapy but became evident 12 weeks later. This suggests that later time points are required to assess induction protocol response.
引用
收藏
页码:631 / 637
页数:7
相关论文
共 8 条
[1]  
BRACHMAN DG, 0513 RTOG
[2]  
POTTER R, 2005, PADIATRISCHE HAMATOL, P578
[3]  
Wagner S, 2005, ANTICANCER RES, V25, P2583
[4]   Valproic acid treatment of glioblastoma multiforme in a child [J].
Witt, O ;
Driever, PH ;
Wolff, J ;
Pekrun, A .
PEDIATRIC BLOOD & CANCER, 2004, 43 (02) :181-181
[5]  
Wolff JEA, 1996, ANTICANCER RES, V16, P805
[6]  
Wolff JEA, 2002, ANTICANCER RES, V22, P3569
[7]  
Wolff JEA, 2000, CANCER, V89, P2131, DOI 10.1002/1097-0142(20001115)89:10<2131::AID-CNCR14>3.0.CO
[8]  
2-J